Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C1S | P09871 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | PLAT | P00750 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
| ▸ | APLNR | P35414 | 3/20 | 0.31 |
| ▸ | AXL | P30530 | 1/20 | 0.30 |
| ▸ | CCR5 | P51681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL878222 | 0.85 | IDO1 (0.36) | C1SIDO1PLATTAAR1APLNR | |
| SCHEMBL883060 | 0.85 | C1S (0.39) | C1SIDO1PLATTAAR1APLNR | |
| SCHEMBL10266425 | 0.84 | C1S (0.36) | C1SIDO1PLATTAAR1APLNR | |
| SCHEMBL12730472 | 0.84 | IDO1 (0.35) | C1SIDO1PLATTAAR1APLNR | |
| SCHEMBL3431041 | 0.83 | C1S (0.35) | C1SIDO1PLATTAAR1APLNR | |
| SCHEMBL1654372 | 0.82 | AXL (0.35) | C1SIDO1PLATTAAR1APLNR | |
| SCHEMBL1688346 | 0.79 | NPC1 (0.36) | PLATTAAR1APLNRAXL | |
| SCHEMBL2624059 | 0.75 | MAPK14 (0.33) | APLNRAXL | |
| SCHEMBL2624061 | 0.75 | PLAT (0.38) | PLATTAAR1AXL | |
| SCHEMBL2624052 | 0.75 | PIK3R2 (0.34) | APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120095211-A1 | SUBSTITUTED PROLINE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120095211-A1 | SUBSTITUTED PROLINE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | INTERMUNE, INC. (US) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095211-A1 | SUBSTITUTED PROLINE INHIBITORS OF HEPATITIS C VIRUS REPLICATION | VIP, EIF2AK2, PREP | C1S 883/4885IDO1 517/4885PLAT 291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.